What Is a GLP-1 Medication
At 48 weeks, the least-squares mean percentage change in body weight was -8.7% in the 1 mg group, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group, and -24.2% in the 12 mg group, compared with -2.1% in the placebo group
It is NOT expected to be approved by the FDA until 2027 or 2028
These drugs mimic a class of hormones called incretins, which enhance the release of insulin in response to ingestion of glucosethe so-called incretin effect. Originally identified in 1987, glucagon-like peptide 1 is a natural protein produced by the body
Oral semaglutide, as a peptidic reference point, requires a strict fasting protocol with a fixed temporal sequence, because the absorption enhancer only works under defined gastric conditions